Melanotan II
MT-II · listed as “MII”
Unapproved non-selective melanocortin agonist used for tanning; linked to safety warnings from regulators.
Not FDA-approved. Not approved anywhere. Subject of FDA, MHRA, and TGA safety warnings. Related afamelanotide (Scenesse) is approved for erythropoietic protoporphyria. This page describes research and public discussion; it is not a recommendation to use.
Overview
Melanotan II was developed at the University of Arizona as a sunless tanning agent. It causes skin darkening and spontaneous erections. Bremelanotide is a metabolite. Regulators in the UK, Australia, and elsewhere warn against its use.
Mechanism of action
Non-selective agonist at MC1R (pigmentation), MC3R and MC4R (sexual function, appetite).
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Early pilot studies B Human clinical data | ~0.025 mg/kg | Every other day | Weeks | Subcutaneous |
Online protocols D Anecdotal / community Product quality unverified. | Highly variable | Variable | — | Subcutaneous / nasal |
Clinical trials & studies
- Human study1998Melanotan II in men with erectile dysfunction (J Urol)
Pilot crossover study; erections in most participants.
- ReviewVariousMelanocytic lesions after melanotan use — case reports
Reports of new or changing moles and melanoma.
Safety
Side effects
- Nausea, facial flushing
- Darkening/new moles
- Spontaneous erections, priapism
- Rare reports of rhabdomyolysis and renal infarction
Contraindications
- History of melanoma or atypical moles
- Cardiovascular disease
Interactions
- PDE5 inhibitors — additive
Long-term safety
Unknown; concern regarding melanocytic lesion changes.
Regulatory status
Unapproved / research
Not approved anywhere. Subject of FDA, MHRA, and TGA safety warnings. Related afamelanotide (Scenesse) is approved for erythropoietic protoporphyria.